What is the recommended taper regimen for Metoprolol (beta blocker)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

A typical metoprolol taper regimen involves gradually reducing the dose over 2-3 weeks to avoid rebound hypertension, tachycardia, or angina, as abrupt discontinuation can lead to sympathetic nervous system overactivity and potentially life-threatening consequences, as highlighted in a recent study 1. When tapering metoprolol, it is essential to consider the patient's individual needs and medical history.

  • For patients on metoprolol tartrate (immediate-release), reduce the dose by 25-50% every 5-7 days, as demonstrated in a study on metoprolol withdrawal phenomena 2.
  • For example, if taking 50 mg twice daily, decrease to 25 mg twice daily for one week, then 25 mg once daily for another week before stopping.
  • For metoprolol succinate (extended-release), reduce from the current dose to half-dose for 7-10 days, then to quarter-dose for another 7-10 days before discontinuation. Patients should monitor blood pressure and heart rate during the taper and report symptoms like chest pain, palpitations, severe headache, or significant blood pressure elevation. The importance of gradual tapering is further emphasized by a study on beta-blockers in hypertension, which highlights the potential risks of abrupt discontinuation 3. Additionally, a study on rebound hypertension following abrupt cessation of clonidine and metoprolol suggests that labetalol may be beneficial in managing hyperadrenergic states following abrupt withdrawal of adrenergic blockers 4. However, the most recent and highest quality study on the topic, published in 2020, emphasizes the need for careful consideration of the beta-blocker rebound phenomenon and its prevention strategies 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.